<DOC>
	<DOCNO>NCT02388919</DOCNO>
	<brief_summary>Evaluate efficacy safety Anlotinib 3-line treatment patient advance non-small lung cancer , placebo control .</brief_summary>
	<brief_title>Study Anlotinib Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）</brief_title>
	<detailed_description>Anlotinib ( AL3818 ) kind innovative medicine approve State Food Drug Administration（SFDA:2011L00661） research Jiangsu Chia-tai Tianqing Pharmaceutical Co. , Ltd. Anlotinib kinase inhibitor receptor tyrosine multi-targets , especially VEGFR1、VEGFR2、VEGFR3、FGFR1/2/3、PDGFRa/β c-Kit MET .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Signed date informed consent 2 . Diagnosed advanced NSCLC ( phase IIIB/IV ) pathology , measurable nidus ( use RECIST 1.1 ) 3. least two systematic chemotherapy upwards 3line treatment suffer 4 . Patients must provide detectable specimen ( tumor tissue hydrothorax ) participating , negative EGFR &amp; ALK participate positive EGFR &amp; ALK , drug tolerance treatment relative target drug 5 . ECOG PS：01 , Expected Survival Time : Over 3 month 6. main organ function normal 7 . The woman patient childbearing age must agree take contraceptive method ( e.g . intrauterine device , contraceptive pill condom ) research within another 6 month ; lactation period examine negative blood serum test urine pregnancy test within 7 day research ; The man patient must agree take contraceptive method research within another 6 month 1. use Anlotinib 2 . Small Cell Lung Cancer ( include small cell cancer kinds cancer mixed nonsmall cell cancer ) 3. examine positive EGFR &amp; ALK mutation detection never take treatment TKIs 4. central lung squamous carcinoma along cavum , nonsmall cell lung cancer along hemoptysis ( &gt; 50ml/day ) 5. kind malignancy within 5 year 6. plan take systemic antitumor therapy within 4 week group medicinetaking period research , include Cytotoxic Therapy , Signal Transduction Inhibitor , Immunotherapy ( use Mitomycin C within 6 week take treatment experimental drug ) ; The patient already take Extended Field Radiotherapy ( EFRT ) within 4 week group Limited Field Radiotherapy propose assessment nidus within 2 week group 7. get non remissive toxic reaction derive previous therapy , level 1 CTC AE ( 4.0 ) , alopecia NOT include 8. kind factor affect oral medicine ( e.g . fail swallow , gastrointestinal tract get resect , chronic diarrhea ileus ) 9. pleural effusion ascites , result respiratory syndrome ( ≥CTC AE level 2 ) 10. symptom brain metastasis control treat within less 2 month 11. get severe disease one control 12. take major surgical treatment , open biopsy , get overt traumatic injury within 28 day group 13. habitus medical history hemorrhage , however severe ; patient non heal wound , ulcer fracture event hemorrhage bleeding ( ≥CTCAE level 3 ) 14. get arterial/venous thrombosis within 6 month , cerebrovascular accident ( include temporary ischemic stoke ) , deevenous thrombosis , pulmonary embolism 15. ever abuse psychiatric drug abstain diagnosed mental disorder 16. participate clinical trial antitumor medicine within 4 week 17. diagnosed disease severely endanger security patient influence completion research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>anlotinib</keyword>
	<keyword>Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Non-small Cell Lung Cancer</keyword>
</DOC>